

# Early Portal Vein Thrombosis After Liver Transplantation: The Role of the Intraoperative Portal Flow After Graft Reperfusion

Received: March 02, 2016; Accepted: April 04, 2016; Published: April 13, 2016

Annabel Blasi<sup>1</sup>,  
Joan Beltran<sup>2</sup>,  
Victor Molina<sup>3</sup>,  
Rocio Garcia<sup>3</sup>,  
Pilar Taura<sup>2</sup> and  
Juan Carlos Garcia-  
Valdecasas<sup>4</sup>

## Background

The incidence of portal vein thrombosis (PVT) after liver transplantation (LT) is considered to be relatively an uncommon complication (1-3%) in comparison to hepatic artery thrombosis, however it can significantly reduce graft and patient survival. Delayed PVT, defined as those appeared one month after LT, does not necessarily lead to graft failure and the main consequences are related to portal hypertension. To the contrary, early PVT potentially resulted in re-transplantation [1-3].

Virchow describes three broad categories of factors that are thought to contribute to thrombosis: hypercoagulability, hemodynamic changes and endothelial injury. In low pressure systems (as it is venous circulation) the hemodynamic factor (blood flow) is considered to play an important role in the development of thrombotic events. For this reason, intraoperative flow measurements (arterial and portal flows) are performed in majority of centers in all patients before bile duct anastomosis during LT. However, these flows are subjected to hemodynamic patient conditions (especially cardiac index and vascular resistances) which are highly variable during and immediately after liver transplantation [4]. Otherwise, some groups suggest the importance of the temporary porto-caval shunt performed during the anhepatic phase to know the conditions before reperfusion and determine whether they will be favorable or not [5].

Although as to be one of the main factors, the role of intraoperative portal flow after graft reperfusion as a contributor to PVT after liver transplantation has not been assessed yet. Our aim is to investigate the correlation between the intraoperative portal flows after graft reperfusion with the appearance of early portal vein thrombosis after LT. Secondly; we investigate the correlation between the temporary porto-caval shunt and the portal flow, also between the cardiac output and the temporary porto-caval shunt and arterial and portal flows after graft reperfusion, during LT.

## Material and Methods

We retrospectively evaluated 452 consecutive LT performed at the Hospital Clinic of Barcelona between January 2009 and May 2015. We excluded 24 liver-kidney, 2 liver-heart combined transplants, 3 patients with Budd Chiari syndrome, and patients who undergo early re-transplant (less than 30 days after the

- 1 Hospital Clinic of Barcelona, Anesthesia Department, Augustine Biomedical Research Institute Pi i Sunyer (IDIBAPS), Spain
- 2 Hospital Clinic de Barcelona, Anesthesia Department, Spain
- 3 Hospital Clinic de Barcelona, Surgery Department, Spain
- 4 Hospital Clinic of Barcelona, Surgery Department, Augustine Biomedical Research Institute Pi i Sunyer (IDIBAPS), Spain

Corresponding author: Annabel Blasi

✉ ablasi@clinic.ub.es

MD, Hospital Clinic de Barcelona, Anesthesia Department, C/Villarroel 170, Barcelona 08036, Spain.

Tel: +34 93 2275558

Fax: +34 93 2279185

first one) due to primary non function or arterial thrombosis (n = 7). Finally, 416 patients were included in the study. The data were collected prospectively and were analyzed retrospectively. Preoperative thrombophilia screening was routinely done in those patients with PVT prior to LT. The MELD (model for end-stage liver disease) score was weighted for hepatocarcinoma according to Sharma and col (range, 6-40) [6]. General anesthesia was performed as previously described [7], and blood products were transfused according to our protocol started from 2007 [8].

Hepatectomy was performed with systematic preservation of the inferior vena cava as well as a temporary terminolateral porto-caval shunt fashioned with continuous 5-0 polypropylene suture. Graft was flushed with 500 cc of Lactate Ringer at 37 C immediately before portal reperfusion. Porto-caval shunt was routinely sectioned before graft implantation, to perform the

anastomosis between the portal vein of the recipient and the portal vein of the graft with continuous 5-0 polypropylene suture. Finally, the hepatic artery anastomosis (with continuous 6-0) and the bile duct anastomosis were completed.

Intraoperative thrombectomy was performed in case of PVT prior to LT, when needed. As it is routine at our institution, intraoperative hepatic artery and portal vein flow in all patients were measured before bile duct anastomosis. Temporary porto-caval shunt flow was also measured during the anhepatic phase. After the measurement of the portal and hepatic artery flows, the portal vein was clamped to assess the augmentation of the hepatic artery flow. Splenic artery ligation was performed when needed, and flow was reassessed after it. Measurements were made with the method for determining the transit time flow, with 8-mm to 12-mm probes used for the portal vein and 3-mm to 5-mm probes used for the hepatic artery; they were monitored with the VeriQ 1001 system (Medi-Stim ASA, Oslo, Norway). Thromboprophylaxis was not routinely given after LT unless intraoperative thrombectomy was performed. If postoperative portal vein thrombosis occurred, anticoagulation was achieved by using low molecular weight heparin or heparin infusion targeting the PTTA values below 1, 5 the upper normal limit. Immunosuppression was administered based on the protocols established at our center. PVT was defined as the absence of flow in part or all the lumen of the portal vein trunk, or portal vein branches, with the presence of solid material within the vein, as documented by doppler ultrasound, and/or angiography; PVT was defined as early or late according to its appearance was before or after 30 days post LT. Medical records were reviewed until 6 months after surgery, death, or re-transplantation. The ethics and research committee of the Hospital Clinic of Barcelona has approved the study.

## Statistical methods

Continuous variables were expressed as median and interquartile range. The chi-square test or the Fisher's exact tests were used for qualitative or dichotomized variables, and the Mann-Whitney test for continuous variables. A two-tailed p value of less than 0.05 was taken as representing significance. Logistic regression analysis was used to find predictive factors for post-operative venous thrombotic event. All analyses were performed with computer software (SPSS, Version 18, SPSS, Inc., Chicago, IL).

## Results

Baseline data characteristics of the 416 LTs at the time of surgery are summarized in **Table 1**. Seventy-one percent of patients were men, with a median age of 56 (50-62) years, MELD 18 (11-23); hepatitis C virus (HCV) positive was the most prevalent etiology (47%).

During the anhepatic phase, values of the temporary porto-caval shunt were of  $1350 \pm 644$  (range from 1000-1750) ml/min. These values correspond to final measurements. In a total of 4 cases porto-caval shunt blood flow was extremely low (<700 ml/min). Identification and ligation of the spontaneous porto-systemic shunt allowed to obtain an adequate blood flow (>1000 ml/min).

At the time of reperfusion, arterial and portal vein blood flows

were  $220 \pm 240$  (160-300) ml/min and  $1500 \pm 666$  (1200-2000) ml/min, respectively. There were any significant differences in values between patients who experienced postoperative PVT vs. those who did not (**Table 2**). The overall incidence of postoperative thrombosis was (5/416, 1,2%). On the other hand, the incidence of preoperative PVT was 10% (42 patients). This fact proves to be a significant factor at the time of developing postoperative PVT: all patients (5 patients) that developed a postoperative PVT, had a partial or complete preoperative PVT.

Thrombophilic study was positive in 8 of the 42 patients with PVT prior to LT (19%) (**Table 1**). No patients with positive

**Table 1** Demographic and intraoperative data of the 416 LT.

	All n = 416	PVT after LT yes n = 5	PVT after LT no n = 411	p
Age, y	56(49-62)	60(51-62)	56(49-62)	0.55
Sex, m (%)	295(71)	1(20)	291(71)	0.9
Body surface, m <sup>2</sup>	1.8(1.7-1.9)	1.7(1.6-1.9)	1.8(1.7-1.9)	0.35
MELD	18(11-23)	25(18-27)	18(11-23)	0.11
Child	9(6-11)	11(9-12)	9(6-11)	0.38
PVT pre LT	42(10)	5(100)	37(9)	<0.01
Etiology of liver disease, n (%)				
HCV	196(47)	1(60)	195(46)	0.14
OH	88(21)	3(20)	85(20)	
AFL	27(7)		27(8)	
Biliary cirrhosis	22(5)		22(6)	
HBV	19(4)		19(4)	
FAP	13(3)		13(3)	
Cryptogenic	10(3)		10(3)	
Autoimmune	7(2)	1(20)	6(2)	
Others	34(8)		34(8)	
HCC, n (%)	174(42)	1(20)	173(42)	
Type of donor, n (%)				
DBD	354(85)	4(80)	350(84)	0.64
LD	29(7)	1(20)	28(8)	
DCD	25(6)		25(6)	
FAP	8(2)		8(2)	
Intraoperative transfusion				
RBC, units	2(0-4)	4(0-5)	2(0-4)	0.58
FFP, ml	0(0-982)	491(0-646)	0(0-991)	0.86
Platelets, n (%)	69(17)	1(20)	68(17)	0.95
Fibrinogen, n (%)	175(42)	2(40)	173(42)	1
Tranexamic acid, y (%)	200(48)	3(60)	197(48)	0.67
Surgical time, min	330(295-385)	285(250-412)	330(295-385)	0.17
Cold ischemia, min	391(300-495)	430(250-495)	390(300-495)	0.98
Warm ischemia, min	30(25-40)	35(25-45)	30(25-40)	0.82

thrombophilic study experienced PVT after LT. Data of patients with PVT after LT is shown in (Table 3). Re-intervention was required in one patient 24h after LT and the rest were successfully managed with anticoagulation by heparin perfusion initially, and low molecular weight heparin thereafter. After six months, all patients maintained a within normal liver function.

Mean values of temporary porto-caval shunt during the anhepatic phase correlated significantly with the portal vein flow after reperfusion of the liver graft ( $R^2$  0.2,  $P < 0.001$ ) (Figure 1). After graft reperfusion, cardiac output moderately correlated

with portal flow ( $R^2$  0.1,  $P < 0.001$ ); but it did not correlate with temporary porto-caval shunt flow, neither with the hepatic artery flow ( $R^2$  0.05,  $P < 0.001$ ), ( $R^2$   $3e^{-4}$ ,  $P$  ns) respectively (Figure 2).

## Discussion

The incidence of PVT after LT in the present series was 1.5%; after adjusting for cardiac output and body surface area, there were no differences in the intraoperative portal flow after graft reperfusion between patients who experienced postoperative PVT and those who did not. These results confirm that PVT after

**Table 2** Intraoperative portal, arterial and porto-caval shunt flow.


	All N = 416	PVT after LT yes n = 5	PVT after LT no N = 411	P
CI	3.9(3.2-5.1)	3.4(3.2-4.5)	3.9(3.2-5.1)	0.4
Portal flow	1500(1200-2000)	1500(1150-2300)	1500(1200-2000)	0.9
Portal flow/CI	842(641-1147)	797(627-1376)	843(641-1147)	0.9
Arterial flow	220(160-300)	180(141-525)	220(160-300)	1
Arterial flow/CI	120(88-162)	93(77-312)	120(87-161)	1
PC shunt flow	1350(1000-1750)	1500(800-)	1350(1000-1750)	0.8
PC shunt flow/CI	755(558-948)	781(462-)	754(559-946)	1

PVT: Portal Vein Thrombosis; CI: Cardiac Index; LT: Liver Transplantation.


**Table 3** Data of 5 patients with PVT after LT.

PVT pre LT	Days after LT	CO	CL	Portal flow	Portal flow BSA	Arterial flow	Arterial flow BSA	Thrombophilic study*
1 yes	1	1.8	3	1500	797	170	90	negative
2 yes	1	2	3	1000	578	113	65	negative
3 yes	1	1.6	3	1300	677	180	93	negative
4 yes	7	3.1	6	3000	1714	740	442	negative
5 yes	28	2.3	4	1600	1038	310	201	negative

LT: Liver Transplantation; CO: Cardiac Output (L/min); CL: Cardiac Index (L/min/m<sup>2</sup>), BSA: Body Surface Area (m<sup>2</sup>); \*Done before LT.



**Figure 1** Correlations between porto-caval shunt flow and portal flow.



**Figure 2** Correlations between cardiac output and porto-caval shunt flow, arterial flow and portal flow. CO: Cardiac Output; BSA: Body Surface Area.

LT is a relatively infrequent event, and suggest that intraoperative portal flow may not be useful to detect patients at high risk of PVT.

Taking into account the importance of Virchow's triad in the pathogenesis of vascular thrombosis, poorly attention is taken until now to the intraoperative blood flow as a contributor to PVT [9]. In our knowledge, this is the first study that aims to correlates the intraoperative portal flow after graft reperfusion with the occurrence of postoperative PVT.

Hepatic and systemic hemodynamic are significantly altered during LT mainly due to general anesthesia, the use of vasopressor drugs and sudden shift of fluids as well [10]. There is an increase in portal flow and a decrease in mean arterial pressure after reperfusion that usually recovers progressively; however, total recovery to normal hemodynamic values may take 2 weeks after LT, with marked reduction in cardiac index and increases in mean arterial pressure, also peripheral vascular resistance [11]. Even two months after LT, further significant increases in peripheral vascular resistance were observed. Since portal flow is highly dependent of cardiac output, it is not surprising that intraoperative measurements of the portal blood flow can

hardly predict portal flow abnormalities that can potentially be involved in postoperative PVT. The poor impact of the portal flow on the occurrence of the PVT in this series, contrast with the contribution to the portal flow described on the development of PVT prior to LT in cirrhotic population, in which decreased portal flow (specifically, portal flow velocity below 15 cm/sc) is a recognized risk factor for this complication [12].

On the other hand, PVT before LT was the only different variable between patients with and without PVT after LT: All PVT after LT were actually, re-thrombosis. In patients with portal vein thrombosis at the time of transplantation, whit the objective to optimize portal blood flow to the graft, the removal of the clot or the clot and the attached intimal layer of the vein is frequently needed (thrombectomy or thrombendvenectomy) [13-16]. This maneuver can injure the endothelial in the thrombus side, making them more prone to re-thrombosis. Considering that the thrombophilic study, the third main contributor to thrombosis, was negative in all LT recipients who displayed PVT after LT, local factors may have a determinant role promoting PVT in this population. In fact, although controversial, re-thrombosis

is a complication more frequently reported in patients with pre transplant PVT, despite properly restoration of the blood flow [1].

We found a moderate correlation between portal flow and temporary porto-caval shunt flow. This result was in accordance with previous results reported by our group in partial grafts. Even though in whole graft this information is not so relevant [17], this finding could be used to identify patients at risk of insufficient portal flow after graft reperfusion, pointing out the need to seek a porto-systemic shunt, which after to be occluded, could improve the portal flow. In our institution, systematic measurements at temporary porto-caval shunt completion, allowed us to identify those patients with a spontaneous porto-systemic shunt and a compromised portal blood flow. Identification of the shunt either preoperatively or during the procedure was of paramount importance in order to obtain a significant flow at reperfusion [5]. For this reason the range of the portal flows was always within adequate limits.

Cardiac index was positively correlated with portal blood, whereas it was not correlated with hepatic artery flow; it is well known that portal flow is mainly dependent on cardiac output, whereas hepatic artery is able to self-regulate the flow [18].

This study shows several weaknesses, in addition to this retrospective nature, the sample size is too small considering the low prevalence of the inquired event, preventing definitive conclusions; all these limitation factors that may do not permit to draw a conclusion; however, it is strongly suggested that intraoperative portal flow is not a good parameter to identify patients at risk of PVT after LT. Moreover, in addition to blood flow, the resistive index which is the ratio of (peak systolic velocity-peak diastolic velocity)/peak systolic velocity) considered as more accurate predictors, was not recorded. Finally, portal flow can be influenced by the graft quality, which was not assessed (e.g. after reperfusion liver biopsy).

To sum up, the results from the present study reassert that early PVT is an infrequent complication after LT, and point to local factors as contributors of this development; whereas portal flow measured after graft reperfusion is not appeared to be able to predict PVT. Even though, porto-caval temporary shunt flow could be used to identify those patients who need some vascular intervention in order to improve the portal flow after reperfusion.

## References

- 1 Duffy JP, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, et al. (2009) Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. *J Am Coll Surg* 208: 896-903.
- 2 Ponziani FR, Zocco MA, Senzolo M, Pompili M, Gasbarrini A, et al. (2014) Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. *Transplant Rev (Orlando)* 28: 92-101.
- 3 Qi X, Dai J, Jia J (2015) Association between Portal Vein Thrombosis and Survival of Liver Transplant Recipients: a Systematic Review and Meta-analysis of Observational Studies. *J Gastrointest Liver Dis* 24: 51-59.
- 4 Gu LH, Fang H, Li FH (2015) Preoperative hepatic hemodynamics in the prediction of early portal vein thrombosis after liver transplantation in pediatric patients with biliary atresia. *Hepatobiliary Pancreat Dis Int* 14: 380-385.
- 5 Sánchez-Cabús S, Abalde JG, Taurá P, Calatayud D, Fondevila C, et al. (2014) Lack of correlation between preoperative and intraoperative liver hemodynamics: a descriptive analysis. *Transplantation* 97: 116-121.
- 6 Wiesner R, Edwards E, Freeman R, Harper A, Kim R, et al. (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology* 124: 91-96.
- 7 Escobar B, Taurá P, Martínez-Palli G, Fondevila C, Balust J, et al. (2014) Stroke volume response to liver graft reperfusion stress in cirrhotic patients. *World J Surg* 38: 927-935.
- 8 Blasi A, Beltran J, Pereira A, Martínez-Palli G, Torrents A, et al. (2012) An assessment of thromboelastometry to monitor blood coagulation and guide transfusion support in liver transplantation. *Transfusion* 52: 1989-1998.
- 9 Kinjo N, Kawanaka H, Akahoshi T, Matsumoto Y, Kamori M, et al. (2014) Portal vein thrombosis in liver cirrhosis. *World J Hepato I* 6: 64-71.
- 10 Paugam-Burtz C, Kavafyan J, Merckx P, Dahmani S, Sommacale D, et al. (2009) Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. *Liver Transpl* 15: 522-529.
- 11 Navasa M, Feu F, García-Pagán JC, Jiménez W, Llach J, et al. (1993) Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. *Hepatology* 17: 355-360.
- 12 Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, et al. (2009) Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. *J Hepatol* 51: 682-689.
- 13 Wu TH, Lin YS, Lee CF, Wu TJ, Yu MC, et al. (2011) Clinical analysis and strategy for liver transplantation in patients with pre-existing portal vein thrombosis. *Chang Gung Med J* 34: 426-434.
- 14 Gao PJ, Gao J, Li Z, Hu ZP, Leng XS, et al. (2015) Liver transplantation in adults with portal vein thrombosis: Data from the China Liver Transplant Registry. *Clin Res Hepatol Gastroenterol*.
- 15 Ramos AP, Reigada CP, Ataíde EC, Almeida JR, Cardoso AR, et al. (2010) Portal vein thrombosis and liver transplantation: long term. *Transplant Proc* 42: 498-501.
- 16 Robles R, Fernandez JA, Hernández Q, Marín C, Ramírez P, et al. (2004) Eversion thromboendovenectomy in organized portal vein thrombosis during liver transplantation. *Clin Transplant* 18: 79-84.
- 17 Hessheimer AJ, Escobar B, Muñoz J, Flores E, Gracia-Sancho J, et al. (2014) Somatostatin therapy protects porcine livers in small-for-size liver transplantation. *Am J Transplant* 14: 1806-1816.
- 18 Dalal A (2016) Anesthesia for liver transplantation. *Transplant Rev (Orlando)* 30: 51-60.